collection
MENU ▼
Read by QxMD icon Read
search

cardiotoxicity

shared collection
70 papers 0 to 25 followers
By Elvis Amao Internal Medicine , Cardiology and infectious diseases
https://www.readbyqxmd.com/read/28066861/the-incidence-of-cardiomyopathy-in-brca1-and-brca2-mutation-carriers-after-anthracycline-based-adjuvant-chemotherapy
#1
Edward J Pearson, Anju Nair, Yahya Daoud, Joanne L Blum
PURPOSE: Breast cancer remains the fourth-leading cause of death in the United States. Nearly 10% of breast cancers are hereditary, with deleterious mutations in BRCA1 and BRCA2 genes being the leading cause. Anthracycline chemotherapy, used commonly for breast cancer, carries cardiotoxicity risk. Recent studies demonstrated anthracycline-induced cardiac failure in homozygous BRCA2-deficient mice and increased rates of heart failure in homozygous BRCA1-deficient mice following ischemic insult...
January 9, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28064155/assessment-of-global-longitudinal-strain-at-low-dose-anthracycline-based-chemotherapy-for-the-prediction-of-subsequent-cardiotoxicity
#2
Clément Charbonnel, Raphaele Convers-Domart, Sophie Rigaudeau, Anne Laure Taksin, Nicolas Baron, Juliette Lambert, Stéphanie Ghez, Jean-Louis Georges, Hassan Farhat, Jérôme Lambert, Philippe Rousselot, Bernard Livarek
AIMS: We sought to assess whether global longitudinal strain (GLS) measured early during treatment with anthracyclines (at a cumulative dose of 150 mg/m(2)) can predict subsequent alterations in left ventricular ejection fraction. METHODS AND RESULTS: Eighty-six patients with Hodgkin's disease, non-Hodgkin's lymphoma, or acute leukaemia and receiving anthracyclines were prospectively included. Patients underwent complete echocardiography on four occasions: baseline (V1); after reaching a cumulative dose of 150 mg/m(2) (V2); end of treatment (V3); and 1 year follow-up (V4)...
January 6, 2017: European Heart Journal Cardiovascular Imaging
https://www.readbyqxmd.com/read/28052002/circulating-mir-1-as-a-potential-biomarker-of-doxorubicin-induced-cardiotoxicity-in-breast-cancer-patients
#3
Vagner Oliveira-Carvalho Rigaud, Ludmila R P Ferreira, Silvia M Ayub-Ferreira, Mônica S Ávila, Sara M G Brandão, Fátima D Cruz, Marília H H Santos, Cecilia B B V Cruz, Marco S L Alves, Victor S Issa, Guilherme V Guimarães, Edécio Cunha-Neto, Edimar A Bocchi
Cardiotoxicity is associated with the chronic use of doxorubicin leading to cardiomyopathy and heart failure. Identification of cardiotoxicity-specific miRNA biomarkers could provide clinicians with a valuable prognostic tool. The aim of the study was to evaluate circulating levels of miRNAs in breast cancer patients receiving doxorubicin treatment and to correlate with cardiac function. This is an ancillary study from "Carvedilol Effect on Chemotherapy-induced Cardiotoxicity" (CECCY trial), which included 56 female patients (49...
December 29, 2016: Oncotarget
https://www.readbyqxmd.com/read/28053628/chemotherapy-induced-left-ventricular-dysfunction-in-patients-with-breast-cancer
#4
Hyun Ju Yoon, Kye Hun Kim, Jong Yoon Kim, Hyuk Jin Park, Jae Yeong Cho, Young Joon Hong, Hyung Wook Park, Ju Han Kim, Youngkeun Ahn, Myung Ho Jeong, Jeong Gwan Cho, Jong Chun Park
PURPOSE: As the numbers of cancer cases and survivors increase, the incidence and natural history of chemotherapy-induced cardiotoxicities in patients with breast cancer may also be expected to change. The present study aimed to investigate the incidence and predictors of chemotherapy-induced left ventricular dysfunction (LVD) in patients with breast cancer. METHODS: From 2003 to 2010, 712 female patients with breast cancer (55.7±10.7 years) were enrolled and divided into the LVD group (n=82, 56...
December 2016: Journal of Breast Cancer
https://www.readbyqxmd.com/read/27931027/anthracycline-induced-cardiotoxicity-in-young-cancer-patients-the-role-of-carnitine
#5
Saro H Armenian
While the increased rates of survival in childhood cancers have increased progressively in recent decades, many childhood cancer survivors will have at least one chronic health condition within 40 years of age. In this regard, cardiovascular complications have emerged as a leading cause of long-term morbidity and mortality in long-term survivors of childhood cancer, likely due to exposure to anthracycline chemotherapy, and outcomes in patients with anthracycline-related cardiomyopathy remain poor. Some progress has been made in understanding the mechanisms at the basis of anthracycline-related cardiomyopathy, which appear to involve generation of reactive oxygen species, leading to mitochondrial dysfunction, followed by myocyte apoptosis and maladaptive left ventricular remodeling...
2016: Annals of Nutrition & Metabolism
https://www.readbyqxmd.com/read/27911951/body-surface-area-and-baseline-blood-pressure-predict-subclinical-anthracycline-cardiotoxicity-in-women-treated-for-early-breast-cancer
#6
Paul Kotwinski, Gillian Smith, Jackie Cooper, Julie Sanders, Louise Ma, Albert Teis, David Kotwinski, Michael Mythen, Dudley J Pennell, Alison Jones, Hugh Montgomery
BACKGROUND AND AIMS: Anthracyclines are highly effective chemotherapeutic agents which may cause long-term cardiac damage (chronic anthracycline cardiotoxicity) and heart failure. The pathogenesis of anthracycline cardiotoxicity remains incompletely understood and individual susceptibility difficult to predict. We sought clinical features which might contribute to improved risk assessment. METHODS: Subjects were women with early breast cancer, free of pre-existing cardiac disease...
2016: PloS One
https://www.readbyqxmd.com/read/27903214/chemotherapy-and-cardiotoxicity-in-hematologic-malignancies-a-review
#7
Antonio Stellitano, Roberta Fedele, Santina Barillà, Antonino Iaria, Carmelo Massimiliano Rao, Massimo Martino
Antineoplastic agents affect the cardiovascular system, and the incidence of cardiotoxicity is continuously growing in patients with hematologic malignancies and treated with antineoplastic therapy. Cardio-oncology is a quite young discipline, designed for diagnosis, prevention and treatment of cardiovascular complications of anticancer agents. Nowadays, with the current treatments and an accurate pharmacological control of comorbidities present at the time of the oncological diagnosis, early clinical events are infrequent, and it seems indeed that cardiotoxicity could emerge as time and years go by, after therapies completion...
November 21, 2016: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/27878803/tissue-doppler-echocardiography-detects-subclinical-left-ventricular-dysfunction-in-patients-undergoing-chemotherapy-for-colon-cancer-insights-from-oncoecho-multicenter-study
#8
Edyta Płońska-Gościniak, Monika Różewicz, Jarosław Kasprzak, Andrzej Wojtarowicz, Katarzyna Mizia-Stec, Tomasz Hryniewiecki, Piotr Pysz, Andrzej Kułach, Artur Bodys, Violetta Sulżyc, Wojciech Braksator, Andrzej Szyszka, Beata Zaborska, Adrianna Gościńska-Szmagała, Maciej Siński, Dariusz Kosior, Ilona Kowalik, Zbigniew Gąsior
I BACKGROUND: Colorectal cancer (CRC) is the second most common cancer in women and the third in men in Poland. The role of chemotherapy (CTX) depends on stage of CRC: adjuvant CTX is a standard treatment in stage III and should also be considered in stage II with risk factors. AIM: The aim of the paper was to assess the cardiovascular consequences of CTX in CRC enrolled to the ONCOECHO multicenter study (2012 - 2014). To identify potential cardiotoxicity we focused on myocardial function, heart rhythm and conduction disorders and adverse cardiovascular events...
November 23, 2016: Kardiologia Polska
https://www.readbyqxmd.com/read/27842711/-radiation-related-heart-toxicity-update-in-women
#9
S Marlière, E Vautrin, C Saunier, A Chaikh, I Gabelle-Flandin
Breast cancer is a common diagnosis in women and thus women are at risk of radiation-induced heart disease, in particular during radiotherapy for left breast cancer and when the internal mammary chain is included. Rates of major cardiac events increase with younger age at the time of irradiation, diagnosis before 1990s, higher radiation doses, coexisting cardiovascular risk factors and adjuvant cardiotoxic chemotherapy. Radiation-induced heart disease comprises a spectrum of cardiac pathologies, including pericardial disease, cardiomyopathy, coronary artery disease and valvular disease...
December 2016: Annales de Cardiologie et D'angéiologie
https://www.readbyqxmd.com/read/27829985/potential-therapeutic-strategies-for-hypertension-exacerbated-cardiotoxicity-of-anticancer-drugs
#10
REVIEW
Robin K Kuriakose, Rakesh C Kukreja, Lei Xi
Despite their recognized cardiotoxic effects, anthracyclines remain an essential component in many anticancer regimens due to their superior antitumor efficacy. Epidemiologic data revealed that about one-third of cancer patients have hypertension, which is the most common comorbidity in cancer registries. The purpose of this review is to assess whether anthracycline chemotherapy exacerbates cardiotoxicity in patients with hypertension. A link between hypertension comorbidity and anthracycline-induced cardiotoxicity (AIC) was first suggested in 1979...
2016: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/27830273/-summary-of-the-esc-position-paper-on-cancer-treatment-and-cardiovascular-toxicity
#11
J Hoog, S Achenbach
The numbers of survivors of cancer have increased as a consequence of advances in chemotherapy; however, the side effects of cancer treatment have become increasingly more important. The most frequent side effects include cardiovascular complications, which can lead to acute and delayed morbidity and mortality, often many years later. The discipline of cardio-oncology deals with the prevention, diagnostics and treatment of cardiovascular diseases caused by cancer therapy. The most important cardiovascular side effects of cytostatic therapy are heart failure due to myocardial dysfunction (cardiotoxicity), coronary artery disease, valvular disease and ventricular arrhythmia as a result of QT extension...
December 2016: Herz
https://www.readbyqxmd.com/read/27816693/are-cardioprotective-effects-of-no-releasing-drug-molsidomine-translatable-to-chronic-anthracycline-cardiotoxicity-settings
#12
Olga Lenčová-Popelová, Hana Jansová, Eduard Jirkovský, Jan Bureš, Anna Jirkovská-Vávrová, Yvona Mazurová, Petra Reimerová, Lucie Vostatková, Michaela Adamcová, Miloš Hroch, Zuzana Pokorná, Petra Kovaříková, Tomáš Šimůnek, Martin Štěrba
Chronic anthracycline (ANT) cardiotoxicity is a serious complication of cancer chemotherapy. Molsidomine, a NO-releasing drug, has been found cardioprotective in different models of I/R injury and recently in acute high-dose ANT cardiotoxicity. Hence, we examined whether its cardioprotective effects are translatable to chronic ANT cardiotoxicity settings without induction of nitrosative stress and interference with antiproliferative action of ANTs. The effects of molsidomine (0.025 and 0.5mg/kg, i.v.) were studied on the well-established model of chronic ANT cardiotoxicity in rabbits (daunorubicin/DAU/3mg/kg/week for 10 weeks)...
November 30, 2016: Toxicology
https://www.readbyqxmd.com/read/27799559/vegf-b-gene-therapy-inhibits-doxorubicin-induced-cardiotoxicity-by-endothelial-protection
#13
Markus Räsänen, Joni Degerman, Tuuli A Nissinen, Ilkka Miinalainen, Risto Kerkelä, Antti Siltanen, Janne T Backman, Eero Mervaala, Juha J Hulmi, Riikka Kivelä, Kari Alitalo
Congestive heart failure is one of the leading causes of disability in long-term survivors of cancer. The anthracycline antibiotic doxorubicin (DOX) is used to treat a variety of cancers, but its utility is limited by its cumulative cardiotoxicity. As advances in cancer treatment have decreased cancer mortality, DOX-induced cardiomyopathy has become an increasing problem. However, the current means to alleviate the cardiotoxicity of DOX are limited. We considered that vascular endothelial growth factor-B (VEGF-B), which promotes coronary arteriogenesis, physiological cardiac hypertrophy, and ischemia resistance, could be an interesting candidate for prevention of DOX-induced cardiotoxicity and congestive heart failure...
November 15, 2016: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/27800661/incidence-time-of-occurrence-and-response-to-heart-failure-therapy-in-patients-with-anthracycline-cardiotoxicity
#14
Arshad A Khan, Asma Ashraf, Rajinder Singh, Aadil Rahim, Walid Rostom, Mumtaz Hussain, Ian Renner, Nicholas J Collins
BACKGROUND: Anthracyclines are commonly used chemotherapeutic medications. AIM: In the current analysis, we evaluated all-cause mortality and incidence, timing and response to medical therapy of anthracycline cardiotoxicity. METHODS: Left ventricular ejection fraction (LVEF) was serially assessed using gated heart pool scan/echocardiography in patients receiving anthracycline-based chemotherapy from January 2009 to December 2014. RESULTS: A total of 1204 patients was administered anthracyclines during the study period...
January 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/27717837/an-integrative-view-of-cisplatin-induced-renal-and-cardiac-toxicities-molecular-mechanisms-current-treatment-challenges-and-potential-protective-measures
#15
REVIEW
George J Dugbartey, Luke J Peppone, Inge A M de Graaf
Cisplatin is currently one of the most widely-used chemotherapeutic agents against various malignancies. Its clinical application is limited, however, by inherent renal and cardiac toxicities and other side effects, of which the underlying mechanisms are only partly understood. Experimental studies show cisplatin generates reactive oxygen species, which impair the cell's antioxidant defense system, causing oxidative stress and potentiating injury, thereby culminating in kidney and heart failure. Understanding the molecular mechanisms of cisplatin-induced renal and cardiac toxicities may allow clinicians to prevent or treat this problem better and may also provide a model for investigating drug-induced organ toxicity in general...
September 14, 2016: Toxicology
https://www.readbyqxmd.com/read/27713603/the-early-predictive-value-of-right-ventricular-strain-in-epirubicin-induced-cardiotoxicity-in-patients-with-breast-cancer
#16
Wei-Ting Chang, Jhih-Yuan Shih, Yin-Hsun Feng, Chun-Yen Chiang, Yu Hsuan Kuo, Wei-Yu Chen, Hong-Chang Wu, Juei-Tang Cheng, Jhi-Joung Wang, Zhih-Cherng Chen
BACKGROUND: As cancer therapies have improved, patient life spans have been extended but quality of life has been threatened by chemotherapy induced cardiotoxicity. Most cardiac complications remain unobserved until specific symptoms develop. Speckle-tracking echocardiography is a sensitive imaging modality in detecting early occult myocardial dysfunction. METHODS: A total number of 35 patients newly diagnosed with breast cancer and preparing for epirubicin therapy were prospectively recruited...
September 2016: Acta Cardiologica Sinica
https://www.readbyqxmd.com/read/27660573/cardio-oncology-a-focused-review-of-anthracycline-human-epidermal-growth-factor-receptor-2-inhibitor-and-radiation-induced-cardiotoxicity-and-management
#17
REVIEW
Jean Domercant, Nichole Polin, Eiman Jahangir
BACKGROUND: Cardio-oncology is a collaborative approach between cardiologists and oncologists in the treatment of patients with cancer and heart disease. Radiation and chemotherapy have played a major role in the decreased cancer-related mortality achieved in the past 2 decades. However, anthracycline-, tyrosine kinase-, and radiation-based therapies are each associated with independent cardiovascular (CV) risks, and these risks are cumulative when these therapies are used in combination...
2016: Ochsner Journal
https://www.readbyqxmd.com/read/27629548/rationale-and-design-of-the-multidisciplinary-team-intervention-in-cardio-oncology-study-titan
#18
Edith Pituskin, Mark Haykowsky, Margaret McNeely, John Mackey, Neil Chua, Ian Paterson
BACKGROUND: Cancer is the leading cause of premature death in Canada. In the last decade, important gains in cancer survival have been achieved by advances in adjuvant treatment. However, many oncologic treatments also result in cardiovascular "toxicity". Furthermore, cardiac risk factors such as hypertension, dyslipidemia, and diabetes mellitus are known to contribute to the progression of cardiac damage and clinical cardiotoxicity. As such, for many survivors, the risk of death from cardiac disease exceeds that of recurrent cancer...
September 15, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27609196/validating-the-pharmacogenomics-of-chemotherapy-induced-cardiotoxicity-what-is-missing
#19
REVIEW
Tarek Magdy, Brian T Burmeister, Paul W Burridge
The cardiotoxicity of certain chemotherapeutic agents is now well-established, and has led to the development of the field of cardio-oncology, increased cardiac screening of cancer patients, and limitation of patients' maximum cumulative chemotherapeutic dose. The effect of chemotherapeutic regimes on the heart largely involves cardiomyocyte death, leading to cardiomyopathy and heart failure, or the induction of arrhythmias. Of these cardiotoxic drugs, those resulting in clinical cardiotoxicity can range from 8 to 26% for doxorubicin, 7-28% for trastuzumab, or 5-30% for paclitaxel...
December 2016: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27566332/echocardiographic-assessment-of-cardiotoxic-effects-of-cancer-therapy
#20
REVIEW
Wendy J Bottinor, Christopher K Migliore, Carrie A Lenneman, Marcus F Stoddard
Patients with cancer can present with difficult management issues, as the medicine can sometimes cause sequelae destructive to healthy tissue. As this population lives longer, cardiotoxic effects are beginning to emerge, but the early recognition of this signal can prove difficult, with too late a recognition leading to lifelong cardiac impairment and dysfunction. Cardio-oncology can bridge this difficulty, and echocardiography and its newer imaging abilities are proving efficacious in this population. This article will address common sequelae of cardiotoxic treatment regimens and offer recommendations for echocardiographic surveillance...
October 2016: Current Cardiology Reports
label_collection
label_collection
6870
1
2
2016-09-11 18:22:58
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"